Cover Image

Tuberculosis Screening in Patients with Psoriasis Receiving Biologic Therapy: A Retrospective Cohort Study

Saved in:

Bibliographic Details
Main Authors:	Igor Snast (Author), Einav Bercovici (Author), Tomer Avni (Author), Dorit Shitenberg (Author), Emmilia Hodak (Author), Lev Pavlovsky (Author)
Format:	Book
Published:	Medical Journals Sweden, 2018-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020)

Melanoma Risk is Increased in Patients with Mycosis Fungoides Compared with Patients with Psoriasis and the General Population*
by: Shany Sherman, et al.
Published: (2020)

IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
by: Shany Sherman, et al.
Published: (2019)

Treatment of Early Folliculotropic Mycosis Fungoides with Special Focus on Psoralen plus Ultraviolet A
by: Iris Amitay-Laish, et al.
Published: (2018)

Trends in Kaposi's Sarcoma Morbidity: A Retrospective Cohort Study of Heart and Lung Transplant Recipients
by: Tal Serlin, et al.
Published: (2021)

Assessment of the risk for tuberculosis in the treatment of psoriasis with biologics: a multicenter retrospective study of 2 704 cases
by: Xia YOU, et al.
Published: (2023)

Improving management of psoriasis patients receiving biological treatment: A qualitative approach
by: Bettina Trettin, et al.
Published: (2021)

Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy
by: Luca Mastorino, et al.
Published: (2022)

Depression, anxiety and adjustment disorder among patients with psoriasis receiving systemic agents: A retrospective cohort study in Quebec, Canada
by: Raymond Milan, et al.
Published: (2023)

Mortality among persons receiving tuberculosis treatment in Itezhi-Tezhi District of Zambia: A retrospective cohort study
by: Eutra Chaaba, et al.
Published: (2023)

Mortality among persons receiving tuberculosis treatment in Itezhi-Tezhi District of Zambia: A retrospective cohort study.
by: Eutra Chaaba, et al.
Published: (2023)

Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study
by: Ji Lecai, et al.
Published: (2023)

Prescribing patterns and persistence of biological therapies for psoriasis management: a retrospective cohort study from Saudi Arabia
by: Ahmad Alamer, et al.
Published: (2024)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020)

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
by: April W. Armstrong, et al.
Published: (2024)

A Study of Humoral Immune Response to Inactivated COVID-19 Vaccine in Patients with Psoriasis Receiving Biologics and Small Molecules
by: Zou Y, et al.
Published: (2024)

Biological Therapy Survivability in Children with Psoriasis: Cohort Study
by: Roman A. Ivanov, et al.
Published: (2021)

Biological therapy of psoriasis
by: Sivamani Raja, et al.
Published: (2010)

Biologics in the management of psoriasis
by: Jennifer D Bahner, et al.
Published: (2009)

Biological treatment of psoriasis
by: Sylwia Słuczanowska-Głąbowska, et al.
Published: (2022)

Flavonoids-Macromolecules Interactions in Human Diseases with Focus on Alzheimer, Atherosclerosis and Cancer
by: Dana Atrahimovich, et al.
Published: (2021)

Injection site reactions due to the use of biologics in patients with psoriasis: A retrospective study
by: Yun Kyung Jang, MD, et al.
Published: (2023)

The Course of Mycosis Fungoides under Cytokine Pathway Blockers: A Multicentre Analysis of Real-Life Clinical Data
by: Iris Amitay-Laish, et al.
Published: (2020)

Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
by: Jashin J. Wu, et al.
Published: (2023)

Can Biologic Agents Improve Treatment Success in Obese Patients With Psoriasis Vulgaris: A Retrospective Review of 320 Patients With Psoriasis Vulgaris
by: Atıl Avcı, et al.
Published: (2024)

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
by: Andreas Pinter, et al.
Published: (2024)

Incidence and Predictors of Adverse Drug Events Among People Receiving Drug Resistant Tuberculosis Treatment in Uganda: 8-Year Retrospective Cohort Study
by: Nasasira M, et al.
Published: (2022)

The other side of biologics for psoriasis
by: Chao-Chun Yang
Published: (2022)

The cost of biologics for psoriasis is increasing
by: Judy Cheng, et al.
Published: (2014)

Biological therapies in psoriasis - revisited
by: Sârbu Maria-Isabela, et al.
Published: (2018)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
by: Yu-Huei Huang, et al.
Published: (2022)

Hidradenitis Suppurativa International Online Community: Patient Characteristics and a Novel Model of Treatment Effectiveness
by: Jen Barak-Levitt, et al.
Published: (2022)

Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data
by: Andreas Pinter, et al.
Published: (2024)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
by: Fabrizio Cantini, et al.
Published: (2017)

Risk factors for actinic keratosis, non‐melanoma skin cancer and cutaneous malignant melanoma in persons with and without Parkinson's disease: A cross‐sectional study
by: Esther Azizi, et al.
Published: (2024)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)

Biologics use in Indian psoriasis patients
by: Murlidhar Rajagopalan, et al.
Published: (2016)

Racial differences in access to psoriasis biologics
by: Shirley P. Parraga, et al.
Published: (2024)

Adverse reactions to biologics for psoriasis and countermeasures
by: Yang YANG, et al.
Published: (2023)

Biologicals in the treatment of psoriasis: The Indian perspective
by: Ajit B Janagond, et al.
Published: (2017)